Julia Marie Eastland
CIK: 0001500189
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- May 14, 2026LNTH
Lantheus Holdings, Inc.
Award(A)Direct4.1K shares- - Feb 9, 2026ZNTL
Zentalis Pharmaceuticals, Inc.
Sale(S)Direct889 shares at avg. $2.39$2K - Feb 6, 2026ZNTL
Zentalis Pharmaceuticals, Inc.
Sale(S)Direct7.9K shares at avg. $2.43$19K - Jan 8, 2026ZNTL
Zentalis Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
775K shares- - May 14, 2025LNTH
Lantheus Holdings, Inc.
Award(A)Direct2.5K shares- - Feb 3, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
Award(A)Direct59.4K shares- - Jan 31, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
Purchase(P)Direct28.5K shares at avg. $1.73$49K - Dec 2, 2024ZNTL
Zentalis Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
3M shares- - Sep 10, 2024LNTH
Lantheus Holdings, Inc.
Award(A)Direct1.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 14, 2026 |  LNTH Lantheus Holdings, Inc. | Award(A) | 4,137 | - | $0 | Direct |
| Feb 9, 2026 |  ZNTL Zentalis Pharmaceuticals, Inc. | Sale(S) | 889 | $2.39 | $2,127 | Direct |
| Feb 6, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | Sale(S) | 7,866 | $2.43 | $19,112 | Direct |
| Jan 8, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 775,000 | - | - | Direct |
| May 14, 2025 | LNTH Lantheus Holdings, Inc. | Award(A) | 2,537 | - | - | Direct |
| Feb 3, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Award(A) | 59,388 | - | - | Direct |
| Jan 31, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Purchase(P) | 28,500 | $1.73 | $49,345 | Direct |
| Dec 2, 2024 | ZNTL Zentalis Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 3,028,800 | - | - | Direct |
| Sep 10, 2024 | LNTH Lantheus Holdings, Inc. | Award(A) | 1,345 | - | $0 | Direct |
1-9 of 9 transactions
About EASTLAND JULIA MARIE
EASTLAND JULIA MARIE (SEC CIK 0001500189) files insider reports with the SEC as Director of Lantheus Holdings, Inc. (LNTH) and CEO & President of Zentalis Pharmaceuticals, Inc. (ZNTL).
Signal8 holds 10 ownership filings by EASTLAND JULIA MARIE (2 Form 3, 8 Form 4), filed between Sep 9, 2024 and May 18, 2026. Those filings report 9 transactions, from Sep 10, 2024 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on EASTLAND JULIA MARIE's filings is in SAN DIEGO, CA.
Recent filings by EASTLAND JULIA MARIE
- May 14, 2026: Grant or award of LNTH shares (Form 4, code A).
- Feb 9, 2026: Open-market sale of ZNTL shares (Form 4, code S).
- Feb 6, 2026: Open-market sale of ZNTL shares (Form 4, code S).
- Jan 8, 2026: Grant or award of ZNTL derivative securities (Form 4, code A).
- May 14, 2025: Grant or award of LNTH shares (Form 4, code A).
Other insiders filing for Lantheus Holdings, Inc. (LNTH)
- Marshall Robert J. Jr., CFO and Treasurer
- Dinkelborg Ludger
- Brown Kimberly, Chief Accounting Officer
- Ber Gerard, Director
- Heino Mary Anne, Executive Chair and CEO
- McHugh Julie, Director